Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP632743.RAcLBxgeTGxTnpKYmjq_uDxo0s-5qrP42-JvI8fJ-cKpw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP632743.RAcLBxgeTGxTnpKYmjq_uDxo0s-5qrP42-JvI8fJ-cKpw130_assertion type Assertion NP632743.RAcLBxgeTGxTnpKYmjq_uDxo0s-5qrP42-JvI8fJ-cKpw130_head.
- NP632743.RAcLBxgeTGxTnpKYmjq_uDxo0s-5qrP42-JvI8fJ-cKpw130_assertion description "[It may be possible to determine the appropriate CY dose in the preconditioning regimen for SCT in FA patients on the basis of the in vitro effects on fragility, and Flu or Ara-C may be a safer drug than high-dose CY for conditioning in FA patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP632743.RAcLBxgeTGxTnpKYmjq_uDxo0s-5qrP42-JvI8fJ-cKpw130_provenance.
- NP632743.RAcLBxgeTGxTnpKYmjq_uDxo0s-5qrP42-JvI8fJ-cKpw130_assertion evidence source_evidence_literature NP632743.RAcLBxgeTGxTnpKYmjq_uDxo0s-5qrP42-JvI8fJ-cKpw130_provenance.
- NP632743.RAcLBxgeTGxTnpKYmjq_uDxo0s-5qrP42-JvI8fJ-cKpw130_assertion SIO_000772 17483082 NP632743.RAcLBxgeTGxTnpKYmjq_uDxo0s-5qrP42-JvI8fJ-cKpw130_provenance.
- NP632743.RAcLBxgeTGxTnpKYmjq_uDxo0s-5qrP42-JvI8fJ-cKpw130_assertion wasDerivedFrom befree-20140225 NP632743.RAcLBxgeTGxTnpKYmjq_uDxo0s-5qrP42-JvI8fJ-cKpw130_provenance.
- NP632743.RAcLBxgeTGxTnpKYmjq_uDxo0s-5qrP42-JvI8fJ-cKpw130_assertion wasGeneratedBy ECO_0000203 NP632743.RAcLBxgeTGxTnpKYmjq_uDxo0s-5qrP42-JvI8fJ-cKpw130_provenance.